Artiva Biotherapeutics Income Statement (2023-2025) | ARTV

Income Statement Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.99M26.66M2.35M0.25M
Operating items
Research & Development 14.77M13.06M11.15M11.16M12.33M13.52M13.32M
Selling, General & Administrative 3.91M2.78M3.17M3.59M3.86M4.81M4.95M
Operating Expenses 18.68M15.85M14.32M14.74M16.19M18.34M18.27M
Operating Income -17.69M10.81M-11.97M-14.49M-16.19M-18.34M-18.27M
EBIT -17.69M10.81M-11.97M-14.49M-16.19M-18.34M-18.27M
Non-operating items
Interest & Investment Income 1.02M0.42M0.58M0.65M0.68M1.85M2.18M
Other Non Operating Income -0.05M0.05M-0.73M-0.27M-2.35M-0.98M
Non Operating Income 0.97M0.47M0.04M0.53M-1.65M0.86M2.17M
Net income details
EBT -16.66M11.23M-11.39M-13.84M-15.51M-16.49M-16.09M
Profit After Tax -16.72M11.28M-12.00M-13.96M-17.84M-17.47M-16.09M
Income from Continuing Operations -16.66M11.23M-11.39M-13.84M-15.51M-16.49M-16.09M
Consolidated Net Income -16.66M11.23M-11.39M-13.84M-15.51M-16.49M-16.09M
Income towards Parent Company -16.66M11.23M-11.39M-13.84M-15.51M-16.49M-16.09M
Net Income towards Common Stockholders -16.66M11.23M-11.39M-13.84M-15.51M-16.49M-16.09M
Additional items
EPS (Basic) -21.0313.98-14.89-17.24-22.00-0.921.35
EPS (Weighted Average and Diluted) -21.031.62-14.89-17.24-22.00-0.921.35
Shares Outstanding (Weighted Average) 8.88M8.88M8.88M24.29M24.29M24.36M24.36M24.43M
Shares Outstanding (Diluted Average) 0.80M6.97M0.80M0.81M0.81M18.90M11.26M24.34M24.38M24.48M
EBITDA -16.72M11.42M-11.96M-14.06M-17.93M-17.25M-16.56M
Shares Outstanding 0.81M0.81M0.81M0.81M3.67M24.29M24.29M24.36M24.39M24.54M